Nivolumab: Promising Survival Signal Coupled with Limited Toxicity Raises Expectations
10:30 Share

This JCO podcast provides observations and commentary on the JCO article, Survival, Durable Tumor Remission, and Long-Term Safety in Patients with Advanced Melanoma Receiving Nivolumab,” by Suzanne Topalian, et al.